DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Namilumab
Drug: Methotrexate
Drug: Folic/folinic acid

First Posted Date: 2015-03-04

Last Posted Date: 2018-09-14

Lead Sponsor: Takeda

Target Recruit Count: 108

Registration Number: NCT02379091

Food Effect Study of Febuxostat XR in Healthy Participants

Phase 1

Completed

Conditions: Gout

Interventions: Drug: Febuxostat XR

First Posted Date: 2015-02-27

Last Posted Date: 2016-04-27

Lead Sponsor: Takeda

Target Recruit Count: 36

Registration Number: NCT02374164

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine
Drug: Placebo

First Posted Date: 2015-02-26

Last Posted Date: 2021-01-06

Lead Sponsor: Takeda

Target Recruit Count: 1106

Registration Number: NCT02371980

Locations: 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Janice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach, West Palm Beach, Florida, United States
🇺🇸
Collaborative Neuroscience Network, LLC, Torrance, California, United States

and more 71 locations

A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SYR-472

First Posted Date: 2015-02-26

Last Posted Date: 2023-12-22

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT02372097

Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

Phase 1

Completed

Conditions: Japanese Healthy Adult Males

Interventions: Drug: TAK-272
Drug: Itraconazole
Drug: Digoxin
Drug: Midazolam

First Posted Date: 2015-02-25

Last Posted Date: 2016-05-23

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT02370615

An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-063
Drug: [^11C]T-773

First Posted Date: 2015-02-25

Last Posted Date: 2015-03-20

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT02370602

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Phase 2

Terminated

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: TAK-448

First Posted Date: 2015-02-24

Last Posted Date: 2017-03-31

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT02369796

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Phase 1

Completed

Conditions: Renal Impairment
Hepatic Impairment

Interventions: Drug: TAK-272

First Posted Date: 2015-02-20

Last Posted Date: 2017-11-06

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT02367872

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Phase 1

Completed

Conditions: Influenza Infection

Interventions: Drug: TAK-850 0.5 mL injection
Drug: TAK-850 0.25 mL injection

First Posted Date: 2015-02-20

Last Posted Date: 2016-04-07

Lead Sponsor: Takeda

Target Recruit Count: 99

Registration Number: NCT02367885

Single-Dose Study of MT203

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: MT203 80 mg or matching Placebo
Drug: MT203 150mg or matching Placebo
Drug: MT203 300 mg or matching placebo

First Posted Date: 2015-02-03

Last Posted Date: 2016-06-20

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT02354599

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy